Latest Regulatory News

LCL Resources reported promising high-grade gold-copper-silver assays from trenching in Papua New Guinea and is actively pursuing lower-risk jurisdiction assets while advancing its Colombian option agreement.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Australian United Investment Company Limited (AUI) has entered into a binding agreement to merge with Diversified United Investment Limited (DUI) through a share exchange scheme, aiming to enhance liquidity, reduce costs, and maintain dividends.

Top End Energy advances its Serpentine hydrogen project and Beetaloo gas exploration while pivoting to power land development for the booming US AI data center sector.

Sierra Nevada Gold (ASX – SNX) has won the bid for the expansive As Safra Copper-Gold Project in Saudi Arabia, marking a major step in its global exploration strategy. Concurrently, drilling progresses at its Nevada Warrior Gold Project with results anticipated soon.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.

Australian Strategic Materials reports a significant 75% jump in NdFeB alloy deliveries at its Korean Metals Plant and advances heavy rare earth production, while announcing a transformative acquisition offer from Energy Fuels Inc.

Taiton Resources has completed drilling at its Challenger West project and is preparing to drill at the Highway project's Yogi prospect, backed by a $2 million capital raise and a key board appointment.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

AdAlta Limited has launched its 'East to West' cellular immunotherapy operations through a strategic collaboration with Shanghai Cell Therapy Group to co-develop BZDS1901, an innovative CAR-T therapy targeting mesothelioma and other solid cancers. The company also strengthened its balance sheet by raising $2.8 million via private placements and repaying key investment agreements.